Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Bladder Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 195 articles:
HTML format



Single Articles


    May 2020
  1. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30192.
    PubMed    


  2. MARIAPPAN P
    Propensity for Quality: No Longer a Tenuous Proposition in Bladder Cancer.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30218.
    PubMed    


  3. VETTERLEIN MW, Gild P, Fisch M, Rink M, et al
    Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of U
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30314.
    PubMed    


  4. BABJUK M
    Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30252.
    PubMed    


    April 2020
  5. WITJES JA, Bruins HM, Cathomas R, Comperat EM, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30230.
    PubMed     Abstract available


  6. WOERL AC, Eckstein M, Geiger J, Wagner DC, et al
    Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30255.
    PubMed     Abstract available


  7. KAMAT AM
    Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30322.
    PubMed    


  8. PANEBIANCO V, Del Giudice F, Leonardo C, Sciarra A, et al
    VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30306.
    PubMed    


  9. LOUIS L, Thomas S, Yohann L, Morgan R, et al
    Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 24. pii: S0302-2838(20)30302.
    PubMed     Abstract available


  10. SHAH A, Grimberg DC, Inman BA
    From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guerin Trials in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30197.
    PubMed    


    March 2020
  11. BAI Y, Yang Y, Tang Y
    Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-0
    Eur Urol. 2020 Mar 18. pii: S0302-2838(20)30149.
    PubMed    


  12. NECCHI A, Gallina A, Dyrskjot L, Roupret M, et al
    Converging Roads to Early Bladder Cancer.
    Eur Urol. 2020 Mar 17. pii: S0302-2838(20)30141.
    PubMed    


  13. MOSTAFID H, Babjuk M, Bochner B, Lerner SP, et al
    Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer.
    Eur Urol. 2020 Mar 16. pii: S0302-2838(20)30146.
    PubMed     Abstract available


  14. BANDINI M, Necchi A
    Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Mus
    Eur Urol. 2020 Mar 14. pii: S0302-2838(20)30150.
    PubMed    


  15. HUDDART R, Hall E, Lewis R, Porta N, et al
    Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherap
    Eur Urol. 2020 Mar 10. pii: S0302-2838(20)30119.
    PubMed    


  16. NECCHI A, Raggi D, Gallina A, Ross JS, et al
    Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Mar 9. pii: S0302-2838(20)30138.
    PubMed     Abstract available


  17. LI R, Sundi D, Zhang J, Kim Y, et al
    Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guerin.
    Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30118.
    PubMed     Abstract available


    February 2020
  18. LIU W, Liu X, Li S
    Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol.
    Eur Urol. 2020 Feb 26. pii: S0302-2838(20)30120.
    PubMed    


  19. KAMOUN A, de Reynies A, Allory Y, Sjodahl G, et al
    Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.
    Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958.
    PubMed    


    January 2020
  20. DEL GIUDICE F, Catto JWF, Panebianco V
    Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI
    Eur Urol. 2020 Jan 28. pii: S0302-2838(20)30056.
    PubMed    


  21. FRAGKOULIS C, Papadopoulos G, Ntoumas K
    Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patient
    Eur Urol. 2020 Jan 21. pii: S0302-2838(20)30053.
    PubMed    


  22. BRIGANTI A, Gandaglia G, Scuderi S, Gallina A, et al
    Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Eur Urol. 2020 Jan 3. pii: S0302-2838(19)30963.
    PubMed     Abstract available


    December 2019
  23. NECCHI A, Bandini M, Calareso G, Raggi D, et al
    Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Eur Urol. 2019 Dec 24. pii: S0302-2838(19)30960.
    PubMed     Abstract available


  24. HUDDART RA, Hall E, Lewis R, Porta N, et al
    Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30840.
    PubMed     Abstract available


  25. THIBAULT C, Lavaud P, Loriot Y
    Studying Rarity in Bladder Cancer.
    Eur Urol. 2019 Dec 4. pii: S0302-2838(19)30891.
    PubMed    


    November 2019
  26. WILLIAMS SB, Black PC, Dyrskjot L, Seiler R, et al
    Re: Aurelie Kamoun, Aurelien de Reynies, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Ne
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874.
    PubMed    


  27. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees.
    Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30763.
    PubMed     Abstract available


  28. DEL GIUDICE F, Barchetti G, De Berardinis E, Pecoraro M, et al
    Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Eur Urol. 2019 Nov 4. pii: S0302-2838(19)30757.
    PubMed     Abstract available


    October 2019
  29. YATAI KB, Tran H, Dunning MJ, Wang D, et al
    Sources of Bias Within Consensus Subtypes of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Oct 23. pii: S0302-2838(19)30760.
    PubMed    


    September 2019
  30. KETTUNEN K, Bostrom P, Taimen P
    Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://do
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30731.
    PubMed    


  31. LIU X
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016: Can Patie
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30734.
    PubMed    


  32. KRIEGMAIR MC, Rother J, Grychtol B, Theuring M, et al
    Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30674.
    PubMed     Abstract available


  33. KAMOUN A, Reynies A, Allory Y, Sjodahl G, et al
    A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30695.
    PubMed     Abstract available


  34. LEOW JJ, Catto JWF, Efstathiou JA, Gore JL, et al
    Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30690.
    PubMed     Abstract available


  35. SHI MJ, Meng XY, Chen CL, Dyrskjot L, et al
    Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Can
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30656.
    PubMed    


    August 2019
  36. VARMA M, Delahunt B, Kwast TV
    Reply to Eva Comperat, Mahul Amin, Victor Reuter's Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. htt
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30676.
    PubMed    


  37. YANG A, Cannataro VL, Townsend JP
    Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30662.
    PubMed    


  38. BABJUK M, Burger M, Comperat EM, Gontero P, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30660.
    PubMed     Abstract available


  39. LU M, Zhang Y, Xiao Y
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016.
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30605.
    PubMed    


  40. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    PubMed    


    July 2019
  41. ELANDER NO, Hussain SA
    Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30593.
    PubMed    


  42. VOSKUILEN CS, van der Heijden MS, van Rhijn BWG
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30543.
    PubMed    


  43. COMPERAT E, Amin M, Reuter V
    Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of Wor
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30541.
    PubMed    


  44. PEDERZOLI F, Bandini M, Briganti A, Plimack ER, et al
    Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.
    Eur Urol. 2019 Jul 11. pii: S0302-2838(19)30522.
    PubMed     Abstract available


    June 2019
  45. KETTUNEN K, Bostrom PJ, Lamminen T, Heinosalo T, et al
    Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30501.
    PubMed     Abstract available


    May 2019
  46. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    PubMed    


  47. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    PubMed    


  48. CAO L, Yang Z, Wang B
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30364.
    PubMed    


  49. VARMA M, Delahunt B, van der Kwast T
    Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30362.
    PubMed     Abstract available


  50. GSCHWEND JE, Heck M
    Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy:
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30346.
    PubMed    


  51. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30344.
    PubMed    


  52. DIJKSTRA S, Wijburg CJ
    Re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71: Can the Pattern of Cancer Recurrence T
    Eur Urol. 2019;75:e137.
    PubMed    


  53. BOCHNER BH, Dalbagni G
    Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outc
    Eur Urol. 2019;75:e138-e139.
    PubMed    


  54. YANG Y, Wei X, Han P
    Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.027.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30343.
    PubMed    


  55. TAGUCHI S, Nakagawa T, Fukuhara H
    Re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30345.
    PubMed    


  56. SUNDAHL N, Vandekerkhove G, Decaestecker K, Meireson A, et al
    Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2019;75:707-711.
    PubMed     Abstract available


    April 2019
  57. SORIA F, Gontero P
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30275.
    PubMed    


  58. SAITA A, Lughezzani G, Buffi NM, Hurle R, et al
    Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging.
    Eur Urol. 2019 Apr 10. pii: S0302-2838(19)30277.
    PubMed     Abstract available


  59. SHI MJ, Meng XY, Lamy P, Banday AR, et al
    APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30261.
    PubMed     Abstract available


  60. GUST KM, Shariat SF
    Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study.
    Eur Urol. 2019;75:695-696.
    PubMed    


  61. LERNER SP, Svatek RS
    What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?
    Eur Urol. 2019;75:612-614.
    PubMed    


  62. MARKOWSKI MC, Boorjian SA, Burton JP, Hahn NM, et al
    The Microbiome and Genitourinary Cancer: A Collaborative Review.
    Eur Urol. 2019;75:637-646.
    PubMed     Abstract available


  63. ABUFARAJ M, Foerster B, Schernhammer E, Moschini M, et al
    Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
    Eur Urol. 2019;75:649-658.
    PubMed     Abstract available


  64. KELLY JD, Tan WS, Porta N, Mostafid H, et al
    BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
    Eur Urol. 2019;75:593-601.
    PubMed     Abstract available


    March 2019
  65. UENO Y, Takeuchi M, Tamada T, Sofue K, et al
    Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.
    Eur Urol. 2019 Mar 25. pii: S0302-2838(19)30198.
    PubMed     Abstract available


  66. MOUW KW, Miyamoto DT, Efstathiou JA
    Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.040: Towards Biomarker-Informed M
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30195.
    PubMed    


  67. CAMPI R, Roupret M
    Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort Study.
    Eur Urol. 2019 Mar 14. pii: S0302-2838(19)30187.
    PubMed    


  68. GAKIS G
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Mar 13. pii: S0302-2838(19)30181.
    PubMed    


  69. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30174.
    PubMed     Abstract available


  70. NARAYAN VM, Lim AH, Dinney CPN
    Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30165.
    PubMed    


  71. RIJNDERS M, van der Veldt AAM, Zuiverloon TCM, Grunberg K, et al
    PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Eur Urol. 2019;75:538-540.
    PubMed    


  72. VAN DIJK N, Funt SA, Blank CU, Powles T, et al
    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    Eur Urol. 2019;75:435-444.
    PubMed     Abstract available


    February 2019
  73. WITJES JA
    Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30163.
    PubMed    


  74. PICHLER R, Heidegger I
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.055.
    Eur Urol. 2019 Feb 22. pii: S0302-2838(19)30159.
    PubMed    


  75. GOLDSTEIN MR, Mascitelli L
    Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.008.
    Eur Urol. 2019 Feb 11. pii: S0302-2838(19)30093.
    PubMed    


  76. CHOUDHURY A, Hoskin PJ
    Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues.
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30086.
    PubMed    


  77. MONTORSI F, Gandaglia G
    Re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641-2.
    Eur Urol. 2019;75:e31.
    PubMed    


  78. FICARRA V, Giannarini G, Crestani A, Palumbo V, et al
    Retrosigmoid Versus Traditional Ileal Conduit for Urinary Diversion After Radical Cystectomy.
    Eur Urol. 2019;75:294-299.
    PubMed     Abstract available


    January 2019
  79. EFSTATHIOU JA, Mouw KW, Gibb EA, Liu Y, et al
    Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30012.
    PubMed     Abstract available


  80. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30075.
    PubMed    


  81. RADZISZEWSKI P, Poletajew S
    Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-G
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30074.
    PubMed    


  82. ZUIVERLOON TCM, Theodorescu D
    Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2019 Jan 17. pii: S0302-2838(18)31024.
    PubMed    


  83. LI R, Tabayoyong WB, Guo CC, Gonzalez GMN, et al
    Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.
    Eur Urol. 2019;75:8-10.
    PubMed     Abstract available


    December 2018
  84. VALENBERG FJPV, Hiar AM, Wallace E, Bridge JA, et al
    Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30959.
    PubMed     Abstract available


  85. TAN TZ, Rouanne M, Huang RY, Thiery JP, et al
    Reply to Pontus Eriksson and Gottfrid Sjodahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 T
    Eur Urol. 2018 Dec 5. pii: S0302-2838(18)30952.
    PubMed    


  86. ERIKSSON P, Sjodahl G
    Re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.08.0
    Eur Urol. 2018 Dec 3. pii: S0302-2838(18)30953.
    PubMed    


  87. VOGELZANG NJ
    Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?
    Eur Urol. 2018;74:754-755.
    PubMed    


    November 2018
  88. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostat
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30942.
    PubMed    


  89. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30941.
    PubMed    


  90. FIORENTINO A, Errico A, Scarcia M
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30881.
    PubMed    


  91. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed    


  92. PANEBIANCO V, Barentsz J, Narumi Y, Catto JWF, et al
    Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imagi
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30720.
    PubMed    


  93. HENRIQUE R, Nunes SP, Jeronimo C
    MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges.
    Eur Urol. 2018 Nov 20. pii: S0302-2838(18)30871.
    PubMed    


  94. GOODSPEED A, Jean A, Costello JC
    A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Eur Urol. 2018 Nov 7. pii: S0302-2838(18)30835.
    PubMed     Abstract available


  95. COLOMBO R, Rocchini L, Suardi N, Benigni F, et al
    Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [Eur Urol 2012;62:797-802].
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30662.
    PubMed    


  96. NECCHI A, Messina A, Briganti A
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria With
    Eur Urol. 2018;74:e107-e108.
    PubMed    


    October 2018
  97. BABJUK M
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30827.
    PubMed    


  98. CHOI W, McConkey DJ
    ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers.
    Eur Urol. 2018 Oct 23. pii: S0302-2838(18)30732.
    PubMed    


  99. GSCHWEND JE, Heck MM, Lehmann J, Rubben H, et al
    Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737.
    PubMed     Abstract available


  100. GORE JL, Wright JL
    Can We Prevent Bladder Cancer Recurrences?
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30749.
    PubMed    


  101. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    PubMed     Abstract available


  102. WITJES JA
    Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30727.
    PubMed    


  103. GRIFFIN JL
    Devil in the Detail: Intratumour Heterogeneity and Personalised Medicine for Bladder Cancer.
    Eur Urol. 2018 Oct 3. pii: S0302-2838(18)30724.
    PubMed    


  104. PIETZAK EJ, Zabor EC, Bagrodia A, Armenia J, et al
    Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2018 Oct 2. pii: S0302-2838(18)30652.
    PubMed     Abstract available


  105. YUH B, Chan K, Wilson T
    Robotic Cystectomy-Moving from Innovation to Measurable Impact.
    Eur Urol. 2018;74:472-473.
    PubMed     Abstract available


    September 2018
  106. TAN WS, Panchal A, Buckley L, Devall AJ, et al
    Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gueri
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30655.
    PubMed     Abstract available


  107. ARENDS TJH, Witjes JA
    Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bac
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30647.
    PubMed    


  108. ABEYSIRI S, Richards T
    Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525-36:
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30664.
    PubMed    


  109. CUMBERBATCH MGK, Jubber I, Black PC, Esperto F, et al
    Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30651.
    PubMed     Abstract available


  110. WARRICK JI, Sjodahl G, Kaag M, Raman JD, et al
    Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30653.
    PubMed     Abstract available


  111. TEOH JYC, Herrmann TRW, Babjuk M
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306.
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30657.
    PubMed    


  112. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30663.
    PubMed    


  113. GARG H, Nayak B, Singh P
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30648.
    PubMed    


  114. DYRSKJOT L
    Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30656.
    PubMed    


  115. TAN TZ, Rouanne M, Tan KT, Huang RY, et al
    Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Eur Urol. 2018 Sep 10. pii: S0302-2838(18)30619.
    PubMed     Abstract available


  116. GIANNARINI G, Crestani A, Ficarra V
    Re: Stenting Prior to Cystectomy Is an Independent Risk Factor for Upper Urinary Tract Recurrence.
    Eur Urol. 2018;74:395-396.
    PubMed    


    August 2018
  117. MOSTAFID H, Palou J, Burger M, Babjuk M, et al
    T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30601.
    PubMed    


  118. LINARES-ESPINOS E, Sanchez-Salas R
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 22. pii: S0302-2838(18)30562.
    PubMed    


  119. GIANNARINI G, Crestani A, Ficarra V
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 20. pii: S0302-2838(18)30564.
    PubMed    


    July 2018
  120. HOVELSON DH, Udager AM, McDaniel AS, Grivas P, et al
    Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Eur Urol. 2018 Jul 19. pii: S0302-2838(18)30475.
    PubMed     Abstract available


  121. PANEBIANCO V, Barentsz J, Narumi Y, Catto J, et al
    Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30457.
    PubMed    


  122. KRANTZ D, Hartana CA, Winerdal ME, Johansson M, et al
    Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
    Eur Urol. 2018 Jul 16. pii: S0302-2838(18)30476.
    PubMed     Abstract available


  123. ECKSTEIN M, Sikic D, Strissel PL, Erlmeier F, et al
    Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30456.
    PubMed    


  124. SONPAVDE G, Dranitsaris G, Necchi A
    Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
    Eur Urol. 2018;74:63-65.
    PubMed    


    June 2018
  125. THOENY HC, Bellin MF, Comperat EM, Thalmann GN, et al
    Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30442.
    PubMed    


    May 2018
  126. PANEBIANCO V, Narumi Y, Altun E, Bochner BH, et al
    Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
    Eur Urol. 2018 May 10. pii: S0302-2838(18)30335.
    PubMed     Abstract available


  127. GEYNISMAN DM, Abbosh PH, Plimack ER, Zibelman M, et al
    Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2018;73:760-762.
    PubMed    


  128. PEEKER R
    Re: Molecular Classification of Urothelial Carcinoma: Global mRNA Classification Versus Tumour-cell Phenotype Classification.
    Eur Urol. 2018;73:809-810.
    PubMed    


  129. KAMAT AM, Li R, O'Donnell MA, Black PC, et al
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review.
    Eur Urol. 2018;73:738-748.
    PubMed     Abstract available


    April 2018
  130. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    PubMed    


  131. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    PubMed    


  132. BOCHNER BH
    Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome.
    Eur Urol. 2018;73:558-559.
    PubMed    


    March 2018
  133. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    PubMed     Abstract available


  134. CUMBERBATCH MGK, Foerster B, Catto JWF, Kamat AM, et al
    Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol. 2018 Mar 6. pii: S0302-2838(18)30121.
    PubMed     Abstract available


    February 2018
  135. EL-ACHKAR A, Kassouf W
    Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Eur Urol. 2018 Feb 14. pii: S0302-2838(18)30088.
    PubMed    


  136. NECCHI A, Anichini A, Sonpavde G
    Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.
    Eur Urol. 2018;73:153-155.
    PubMed    


  137. WILSON SS, Crawford ED
    Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
    Eur Urol. 2018;73:233-235.
    PubMed    


  138. SZABADOS B, van Dijk N, Tang YZ, van der Heijden MS, et al
    Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
    Eur Urol. 2018;73:149-152.
    PubMed     Abstract available


    January 2018
  139. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    PubMed    


    December 2017
  140. SAITO R, Kobayashi T, Ogawa O
    Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31042.
    PubMed    


  141. PANG KH, Noon AP
    Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31039.
    PubMed    


  142. OOSTERLINCK W, Decaestecker K
    Re: Active Surveillance for Low-risk Nonmuscle Invasive Bladder Cancer (NMIBC): a Confirmatory and Resource Consumption Study from Bladder Cancer Italian Active Surveillance (BIAS) Project.
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31018.
    PubMed    


  143. CUMBERBATCH MG, Catto JWF
    Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31007.
    PubMed    


    November 2017
  144. ODDENS JR, de Reijke TM
    The Current State of Predicting Response on Bacillus Calmette-Guerin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
    Eur Urol. 2017 Nov 30. pii: S0302-2838(17)31006.
    PubMed    


  145. CHOI W, McConkey D
    Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in The Cancer Genome Atl
    Eur Urol. 2017 Nov 23. pii: S0302-2838(17)30979.
    PubMed    


  146. LINSCOTT JA, Smith AB, Sammon JD
    Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30971.
    PubMed    


  147. ABUFARAJ M, Dalbagni G, Daneshmand S, Horenblas S, et al
    The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840.
    PubMed     Abstract available


    October 2017
  148. MAIA MC, Grivas P, Agarwal N, Pal SK, et al
    Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30902.
    PubMed    


    September 2017
  149. OHNO Y
    Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Sep 26. pii: S0302-2838(17)30780.
    PubMed    


  150. BIRKENKAMP-DEMTRODER K, Christensen E, Nordentoft I, Knudsen M, et al
    Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30775.
    PubMed     Abstract available


    August 2017
  151. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    PubMed     Abstract available


    July 2017
  152. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    PubMed     Abstract available


    June 2017
  153. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    PubMed    


  154. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    PubMed    


  155. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    PubMed     Abstract available


  156. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    PubMed    


  157. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    PubMed    


  158. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    PubMed     Abstract available


  159. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    PubMed     Abstract available


  160. CHEVALIER MF, Bohner P, Pieraerts C, Lhermitte B, et al
    Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Eur Urol. 2017;71:854-857.
    PubMed     Abstract available


  161. WANG L, Sustic T, Leite de Oliveira R, Lieftink C, et al
    A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Eur Urol. 2017;71:858-862.
    PubMed     Abstract available


    May 2017
  162. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    PubMed    


  163. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    PubMed    


  164. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    PubMed    


  165. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    PubMed    


  166. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    PubMed     Abstract available


  167. COLLINS JW, Hosseini A, Adding C, Nyberg T, et al
    Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.
    Eur Urol. 2017;71:723-726.
    PubMed     Abstract available


    April 2017
  168. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    PubMed     Abstract available


  169. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    PubMed    


  170. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    PubMed    


  171. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    PubMed     Abstract available


  172. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    PubMed     Abstract available


  173. GAKIS G, Black PC, Bochner BH, Boorjian SA, et al
    Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
    Eur Urol. 2017;71:545-557.
    PubMed     Abstract available


    March 2017
  174. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    PubMed     Abstract available


  175. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    PubMed    


  176. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Abstract available


  177. BABJUK M, Bohle A, Burger M, Capoun O, et al
    EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Eur Urol. 2017;71:447-461.
    PubMed     Abstract available


    February 2017
  178. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    PubMed    


  179. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    PubMed    


  180. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    PubMed    


    January 2017
  181. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    PubMed    


  182. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    PubMed     Abstract available


  183. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    PubMed    


  184. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    PubMed     Abstract available


    December 2016
  185. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    PubMed    


    October 2016
  186. LIEDBERG F, Jancke G, Sorenby A, Kannisto P, et al
    Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30713.
    PubMed     Abstract available


  187. NECCHI A, Giardiello D, Mariani L
    Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30684.
    PubMed    


    September 2016
  188. LUO HL, Chen YT, Cheng YT, Chiang PH, et al
    Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Can
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30663.
    PubMed    


  189. SEISEN T, Babjuk M, Roupret M
    Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30662.
    PubMed    


    April 2016
  190. PICKARD R
    Is Robot-assisted Cystectomy Better than Open?--Nearing an Answer after a Decade of Use.
    Eur Urol. 2016;69:622-3.
    PubMed    


  191. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    PubMed     Abstract available


    March 2016
  192. HAMILTON-REEVES JM, Bechtel MD, Hand LK, Schleper A, et al
    Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.
    Eur Urol. 2016;69:389-92.
    PubMed     Abstract available


    February 2016
  193. SATKUNASIVAM R, Santomauro M, Chopra S, Plotner E, et al
    Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life.
    Eur Urol. 2016;69:247-53.
    PubMed     Abstract available


  194. KAMAT AM, Briggman J, Urbauer DL, Svatek R, et al
    Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin.
    Eur Urol. 2016;69:197-200.
    PubMed     Abstract available


  195. SYLVESTER RJ, Oosterlinck W, Holmang S, Sydes MR, et al
    Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carci
    Eur Urol. 2016;69:231-44.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: